{"organizations": [], "uuid": "3fd09f7f55b3313fb3248d72742d33902a789199", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "https://fm.cnbc.com/applications/cnbc.com/resources/img/editorial/2016/01/13/103301392-20160111-2-1907.1910x1000.jpg", "site_section": "http://www.cnbc.com/id/19746125/device/rss/rss.xml#", "section_title": "Top News and Analysis (pro)", "url": "https://www.cnbc.com/2018/05/01/pfizers-quarterly-profit-rises-14-percent.html", "country": "US", "domain_rank": 767, "title": "Pfizer's quarterly profit rises 14%", "performance_score": 0, "site": "cnbc.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "blogs", "published": "2018-05-01T13:55:00.000+03:00", "replies_count": 0, "uuid": "3fd09f7f55b3313fb3248d72742d33902a789199"}, "author": "", "url": "https://www.cnbc.com/2018/05/01/pfizers-quarterly-profit-rises-14-percent.html", "ord_in_thread": 0, "title": "Pfizer's quarterly profit rises 14%", "locations": [], "entities": {"persons": [{"name": "ian read", "sentiment": "negative"}], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "pfizer", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Pfizer's quarterly revenue missed analysts' estimates on Tuesday, hurt by lower-than-expected sales of blockbuster breast cancer drug Ibrance and arthritis drug Xeljanz.\nIbrance raked in sales of $933 million in the first quarter, up 37.4 percent from a year earlier, but missed analysts' estimates of $956.6 million, according to Thomson Reuters I/B/E/S.\nThe drug faces competition from Novartis' Kisqali and Lilly's recently approved Verzenio.\nXeljanz, which is approved to treat rheumatoid arthritis and psoriatic arthritis, posted sales of $326 million, well below $398.5 million expected by analysts.\nShares of the largest U.S. drugmaker fell 1.67 percent to $36 in premarket trading on Tuesday.\nPfizer, which has been exploring options for its consumer healthcare business, said it expected to make a decision in 2018.\nThe company hoped to bring in $20 billion through an auction for the business, which includes Centrum vitamins and Advil painkillers.\nPfizer's quarterly profit, however, topped Wall Street estimates on stronger-than-expected sales of pneumonia vaccine Prevnar. The company also reaffirmed its 2018 forecast.\nPrevnar recorded sales of $1.38 billion, which was slightly better than what analysts were expecting.\nNet profit rose to $3.56 billion, or 59 cents per share, in the latest quarter ended April 1 from $3.12 billion, or 51 cents per share, a year earlier.\nExcluding items, the company earned 77 cents per share, topping estimates of 74 cents.\nTotal revenue rose 1 percent to $12.91 billion, while analysts were expecting $13.13 billion.", "external_links": [], "published": "2018-05-01T13:55:00.000+03:00", "crawled": "2018-05-01T14:11:40.023+03:00", "highlightTitle": ""}